E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bronchopulmonary dysplasia |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine if treatment with very low dose dexamethasone facilitates the extubation of ventilator dependent preterm babies of less than 30 weeks' gestation who are at high risk of developing BPD.
The main outcome measure is the time from randomisation to first extubation, when the baby remains extubated for more than 24 hours. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to determine if the treatment of ventilator dependent preterm babies of less than 30 weeks' gestation who are at high risk of developing BPD with very low dose dexamethasone impacts upon:
1. Time to first extubation (whether or not more than 24 hours) 2. Rates of extubation by day 7 after randomisation (for more than 24 hours) 3. Rates of extubation by day 7 after randomisation (whether or not more than 24 hours) 4. Survival to 36 weeks' post menstrual age (PMA) 5. Markers of respiratory morbidity to 36 weeks' PMA (or discharge if sooner). 6. Cytokine profile (this assesses the inflammatory markers within the body) 7. Safety outcomes 8. Parent/ family experience
The tertiary objectives are to assess the acceptability and feasibility of the trial in order to inform the design of the subsequent effectiveness trial by reporting metrics related to: 1. Recruitment 2. Retention 3. Adherence to protocol 4. Completeness of data |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion Criteria Eligible babies: 1. Born at <30 weeks’ gestation 2. Aged between 10 and 24 postnatal days (≥10 and ≤24) 3. At high risk of developing BPD: receiving mechanical ventilation via ET tube with at least 30% inspired oxygen when the PEEP is at least 4 cm water and, in the opinion of the treating physician, unlikely to be extubated within 48 hours 4. Receiving caffeine therapy 5. Written informed parental consent 6. Born to a mother aged 16 or over
Parents of babies recruited at Leeds Teaching Hospitals and Bradford Royal Infirmary will be asked to consent to their baby having samples taken for cytokine estimation. This will allow modelling of their inflammatory networks. |
|
E.4 | Principal exclusion criteria |
Exclusion Criteria Ineligible babies: 1. Previously received postnatal steroid treatment for respiratory disease 2. No realistic prospect of survival 3. Severe congenital anomaly affecting the lungs, heart or central nervous system 4. Previous surgical abdominal procedure 5. Concurrent illness for which postnatal corticosteroid would be contra-indicated (e.g. active fungal infection, confirmed or suspected acute sepsis and acute NEC/focal intestinal perforation) 6. Participation in another trial that would preclude baby from inclusion in Minidex
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time (days) to extubation after randomisation when the baby remains extubated for more than 24 hours |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Date of the database lock. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 30 |